118 related articles for article (PubMed ID: 34507017)
21. Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy.
Grupp K; Höhne TS; Prien K; Hube-Magg C; Tsourlakis MC; Sirma H; Pham T; Heinzer H; Graefen M; Michl U; Simon R; Wilczak W; Izbicki J; Sauter G; Minner S; Schlomm T; Steurer S
Exp Mol Pathol; 2013 Oct; 95(2):227-34. PubMed ID: 23948277
[TBL] [Abstract][Full Text] [Related]
22. Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment.
Fontugne J; Lee D; Cantaloni C; Barbieri CE; Caffo O; Hanspeter E; Mazzoleni G; Dalla Palma P; Rubin MA; Fellin G; Mosquera JM; Barbareschi M; Demichelis F
Cancer Epidemiol Biomarkers Prev; 2014 Apr; 23(4):594-600. PubMed ID: 24515272
[TBL] [Abstract][Full Text] [Related]
23. Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion.
Gumuskaya B; Gurel B; Fedor H; Tan HL; Weier CA; Hicks JL; Haffner MC; Lotan TL; De Marzo AM
Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):209-15. PubMed ID: 23545904
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of ERG and PTEN protein expression in cribriform architecture prostate carcinomas.
Downes MR; Satturwar S; Trudel D; van der Kwast TH
Pathol Res Pract; 2017 Jan; 213(1):34-38. PubMed ID: 27913052
[TBL] [Abstract][Full Text] [Related]
25. Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers.
Burdelski C; Bujupi E; Tsourlakis MC; Hube-Magg C; Kluth M; Melling N; Lebok P; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Simon R; Schlomm T; Steurer S; Krech T
PLoS One; 2015; 10(6):e0128525. PubMed ID: 26030748
[TBL] [Abstract][Full Text] [Related]
26. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer.
Bismar TA; Yoshimoto M; Vollmer RT; Duan Q; Firszt M; Corcos J; Squire JA
BJU Int; 2011 Feb; 107(3):477-85. PubMed ID: 20590547
[TBL] [Abstract][Full Text] [Related]
27. The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion.
Burdelski C; Menan D; Tsourlakis MC; Kluth M; Hube-Magg C; Melling N; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Simon R; Schlomm T; Steurer S; Krech T
BMC Cancer; 2015 Jul; 15():538. PubMed ID: 26202067
[TBL] [Abstract][Full Text] [Related]
28. Identification of Combinatorial Genomic Abnormalities Associated with Prostate Cancer Early Recurrence.
Qu X; Jeldres C; Glaskova L; Friedman C; Schroeder S; Nelson PS; Porter C; Fang M
J Mol Diagn; 2016 Mar; 18(2):215-24. PubMed ID: 26752304
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical expression of mismatch repair proteins (MSH2, MSH6, MLH1, and PMS2) in prostate cancer: correlation with grade groups (WHO 2016) and ERG and PTEN status.
Albero-González R; Hernández-Llodrà S; Juanpere N; Lorenzo M; Lloret A; Segalés L; Duran X; Fumadó L; Cecchini L; Lloreta-Trull J
Virchows Arch; 2019 Aug; 475(2):223-231. PubMed ID: 31209634
[TBL] [Abstract][Full Text] [Related]
30. High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions.
Grupp K; Wilking J; Prien K; Hube-Magg C; Sirma H; Simon R; Steurer S; Budäus L; Haese A; Izbicki J; Sauter G; Minner S; Schlomm T; Tsourlakis MC
Eur J Cancer; 2014 Mar; 50(4):852-61. PubMed ID: 24380696
[TBL] [Abstract][Full Text] [Related]
31. SPINK1 protein expression and prostate cancer progression.
Flavin R; Pettersson A; Hendrickson WK; Fiorentino M; Finn S; Kunz L; Judson GL; Lis R; Bailey D; Fiore C; Nuttall E; Martin NE; Stack E; Penney KL; Rider JR; Sinnott J; Sweeney C; Sesso HD; Fall K; Giovannucci E; Kantoff P; Stampfer M; Loda M; Mucci LA
Clin Cancer Res; 2014 Sep; 20(18):4904-11. PubMed ID: 24687926
[TBL] [Abstract][Full Text] [Related]
32. SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence.
Hernández-Llodrà S; Segalés L; Juanpere N; Marta Lorenzo T; Salido M; Nonell L; David López T; Rodríguez-Vida A; Bellmunt J; Fumadó L; Cecchini L; Lloreta-Trull J
Prostate; 2021 Dec; 81(16):1267-1277. PubMed ID: 34533858
[TBL] [Abstract][Full Text] [Related]
33. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis.
Pettersson A; Graff RE; Bauer SR; Pitt MJ; Lis RT; Stack EC; Martin NE; Kunz L; Penney KL; Ligon AH; Suppan C; Flavin R; Sesso HD; Rider JR; Sweeney C; Stampfer MJ; Fiorentino M; Kantoff PW; Sanda MG; Giovannucci EL; Ding EL; Loda M; Mucci LA
Cancer Epidemiol Biomarkers Prev; 2012 Sep; 21(9):1497-509. PubMed ID: 22736790
[TBL] [Abstract][Full Text] [Related]
34. Aquaporin 5 expression is frequent in prostate cancer and shows a dichotomous correlation with tumor phenotype and PSA recurrence.
Pust A; Kylies D; Hube-Magg C; Kluth M; Minner S; Koop C; Grob T; Graefen M; Salomon G; Tsourlakis MC; Izbicki J; Wittmer C; Huland H; Simon R; Wilczak W; Sauter G; Steurer S; Krech T; Schlomm T; Melling N
Hum Pathol; 2016 Feb; 48():102-10. PubMed ID: 26614400
[TBL] [Abstract][Full Text] [Related]
35. Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy.
Hamid AA; Gray KP; Huang Y; Bowden M; Pomerantz M; Loda M; Sweeney CJ
Eur Urol Oncol; 2019 Sep; 2(5):475-482. PubMed ID: 31411988
[TBL] [Abstract][Full Text] [Related]
36. PTEN and ERG expression in MRI-ultrasound guided fusion biopsy correlated with radical prostatectomy findings in men with prostate cancer.
Erickson AM; Lokman U; Lahdensuo K; Tornberg S; Visapaa H; Bergroth R; Santti H; Petas A; Rannikko AS; Mirtti T
Prostate; 2020 Sep; 80(13):1118-1127. PubMed ID: 32634262
[TBL] [Abstract][Full Text] [Related]
37. Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset.
Hernández S; Font-Tello A; Juanpere N; de Muga S; Lorenzo M; Salido M; Fumadó L; Serrano L; Cecchini L; Serrano S; Lloreta J
Prostate; 2016 Jun; 76(9):854-65. PubMed ID: 26959281
[TBL] [Abstract][Full Text] [Related]
38. Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG-fusion positive and PTEN deleted prostate cancers.
Burdelski C; Kleinhans S; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Tsourlakis MC; Wilczak W; Marx A; Sauter G; Wittmer C; Huland H; Simon R; Schlomm T; Steurer S
Int J Cancer; 2016 Mar; 138(5):1199-206. PubMed ID: 26383228
[TBL] [Abstract][Full Text] [Related]
39. SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence.
Grupp K; Diebel F; Sirma H; Simon R; Breitmeyer K; Steurer S; Hube-Magg C; Prien K; Pham T; Weigand P; Michl U; Heinzer H; Kluth M; Minner S; Tsourlakis MC; Izbicki JR; Sauter G; Schlomm T; Wilczak W
Prostate; 2013 Nov; 73(15):1690-8. PubMed ID: 23843146
[TBL] [Abstract][Full Text] [Related]
40. Single-cell genetic analysis reveals insights into clonal development of prostate cancers and indicates loss of PTEN as a marker of poor prognosis.
Heselmeyer-Haddad KM; Berroa Garcia LY; Bradley A; Hernandez L; Hu Y; Habermann JK; Dumke C; Thorns C; Perner S; Pestova E; Burke C; Chowdhury SA; Schwartz R; Schäffer AA; Paris PL; Ried T
Am J Pathol; 2014 Oct; 184(10):2671-86. PubMed ID: 25131421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
